Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma
Adjuvant nivolumab is superior to standard of care ipilimumab in patients with surgically resected stage III/IV melanoma who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented ...
Sep 11, 2017
0
0